PROVECTUS BIOPHARMS (PVCT) Total Assets by Year
PROVECTUS BIOPHARMS closed fiscal year 2025 with $698K in total assets, $7.0M in total liabilities and -$6.3M in shareholder equity. This represents a decrease of 30.7% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters PROVECTUS BIOPHARMS has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
PVCT Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $698K-30.7% | $1.0M-30.5% | $1.4M-28.9% | $2.0M-42.0% | $3.5M+496.3% | $589K-60.1% | $1.5M-25.7% | $2.0M-42.1% | $3.4M-38.8% | $5.6M-72.5% | $20.4M-21.9% | $26.2M+30.9% | $20.0M+222.5% | $6.2M-53.5% | $13.3M |
| Total Liabilities | $7.0M+0.4% | $7.0M-22.9% | $9.0M+9.4% | $8.3M+7.3% | $7.7M-75.0% | $30.8M+20.5% | $25.5M+31.7% | $19.4M+44.2% | $13.5M+528.2% | $2.1M-48.1% | $4.1M+314.7% | $994K-92.6% | $13.4M+638.8% | $1.8M-45.6% | $3.3M |
| Total Equity | -$6.3M-5.7% | -$6.0M+21.5% | -$7.6M-21.9% | -$6.2M-48.7% | -$4.2M+86.1% | -$30.2M-25.5% | -$24.1M-38.2% | -$17.4M-73.8% | -$10.0M-388.8% | $3.5M-78.7% | $16.3M-35.2% | $25.2M+280.0% | $6.6M+50.9% | $4.4M-56.2% | $10.0M |
PVCT Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5M+104.0% | $578K-13.3% | $698K-30.7% | $420K-47.6% | $722K-15.7% | $666K-38.3% | $1.0M-30.5% | $802K-52.5% | $856K-49.2% | $1.1M-37.3% | $1.4M-28.9% | $1.7M-17.6% |
| Total Liabilities | $7.8M+17.6% | $7.3M+27.4% | $7.0M+0.4% | $6.6M+5.8% | $6.6M-21.2% | $5.7M-32.8% | $7.0M-22.9% | $6.2M-32.4% | $8.4M-6.8% | $8.5M-2.2% | $9.0M+9.4% | $9.2M+3.4% |
| Total Equity | -$6.3M-6.9% | -$6.7M-31.8% | -$6.3M-5.7% | -$6.2M-13.4% | -$5.9M+21.9% | -$5.1M+31.5% | -$6.0M+21.5% | -$5.4M+27.9% | -$7.5M-3.0% | -$7.4M-6.4% | -$7.6M-21.9% | -$7.5M-9.6% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More PROVECTUS BIOPHARMS financials
Frequently Asked Questions
What was PROVECTUS BIOPHARMS's total assets in fiscal year 2025?
PROVECTUS BIOPHARMS closed fiscal year 2025 with $698K in total assets, $7.0M in total liabilities and -$6.3M in shareholder equity.
How fast is PROVECTUS BIOPHARMS's total assets growing?
PROVECTUS BIOPHARMS (PVCT) total assets fell by 30.7% year over year, from $1.0M to $698K in fiscal year 2025.
How has PROVECTUS BIOPHARMS's total assets changed over the years?
Across the 15 fiscal years this page covers, PROVECTUS BIOPHARMS (PVCT) total assets went from $13.3M in fiscal year 2011 to $698K in fiscal year 2025.
What was PROVECTUS BIOPHARMS's total assets in the most recent quarter?
PROVECTUS BIOPHARMS (PVCT) reported $1.5M in total assets in Q2 2026. This represents an increase of 104.0% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what PROVECTUS BIOPHARMS (PVCT) reported on that line in every period on record.